Sign In
Buy ACXP
$1.80
-0.130 (-6.74%)
At Close: Jun 02, 2026
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
11:00am, Tuesday, 12'th May 2026
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
07:01am, Tuesday, 12'th May 2026
STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics fo
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
08:00am, Monday, 04'th May 2026
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with m
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
08:00am, Wednesday, 29'th Apr 2026
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
08:00am, Monday, 27'th Apr 2026
Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new clas
STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
04:01pm, Thursday, 16'th Apr 2026
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Ac
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:00am, Thursday, 16'th Apr 2026
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Ac
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
10:41am, Thursday, 02'nd Apr 2026
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
07:01am, Monday, 30'th Mar 2026
STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecu
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?
10:55am, Thursday, 19'th Mar 2026
The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 17'th Mar 2026
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Drop in Short Interest
01:40am, Sunday, 15'th Mar 2026
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP - Get Free Report) saw a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 57,707 shares,
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
01:02pm, Friday, 13'th Mar 2026
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
07:01am, Friday, 13'th Mar 2026
STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
